Shinpoong Pharmaceutical Co., Ltd. Overview
Pro stress-test →Shinpoong Pharmaceutical manufactures and sells pharmaceutical products in South Korea, offering cephalosporin antibiotics, penicillin antibiotics, antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. The company exports its products to approximately 50 countries.
Strategic Profile
Pro stress-test →The company provides active pharmaceutical ingredients, Pyramax (an anti-malarial drug), and drugs for treating hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and surgical adhesion barriers, plus prescription drugs, wound dressings, health functional food, and over-the-counter products. The company maintains a diversified portfolio spanning generic antibiotics to specialized therapeutics, positioning itself as a vertically-integrated domestic Korean pharmaceutical player.
Competitive Landscape
Pro stress-test →Shinpoong competes within the South Korean pharmaceutical market alongside established players like Samsung Pharm, Yuhan Corp, Boryung Corp, and GC Biopharma. As a mid-sized domestic player with ~840 employees, the company focuses on generic and specialty pharmaceuticals rather than biotech innovation, positioning it against larger multinational generics manufacturers and regional healthcare conglomerates.
Industry Context
Shinpoong Pharmaceutical Co., Ltd. operates in Pharmaceuticals and Healthcare.
Key facts
Founded: 1962 · Headquarters: Seoul, South Korea · Employees: 840 · Revenue: $162.2M · Market cap: $503.6M